Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain–Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma

Carmen Oi Ning Leung, Man Tong, Katherine Po Sin Chung, Lena Zhou, Noélia Che, Kwan Ho Tang, Jin Ding, Eunice Yuen Ting Lau, Irene Oi Lin Ng, Stephanie Ma, Terence Kin Wah Lee – 14 October 2019

Outcome of Liver Transplant Patients With Preformed Donor‐Specific Anti–Human Leukocyte Antigen Antibodies

Arnaud Del Bello, Martine Neau‐Cransac, Laurence Lavayssiere, Valérie Dubois, Nicolas Congy‐Jolivet, Jonathan Visentin, Marie Danjoux, Brigitte Le Bail, Valérie Hervieu, Olivier Boillot, Teresa Antonini, Nassim Kamar, Jérôme Dumortier – 14 October 2019 – After liver transplantation (LT), the role of preformed donor‐specific anti–human leukocyte antigen antibodies (pDSAs) remains incompletely understood. We conducted a retrospective, case‐control analysis to determine the impact of pDSAs after LT in 3 French transplant centers (Bordeaux, Lyon, and Toulouse).

Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma

Giuseppe Cullaro, Jessica B. Rubin, Neil Mehta, Jennifer C. Lai – 14 October 2019 – Hepatocellular carcinoma (HCC) is the fastest‐rising cause of cancer‐related mortality in the United States and is a leading indication for liver transplantation (LT). Changes have been noted in the age of the population with chronic liver disease, but how this change affects patients with HCC is unknown. This study aims to characterize trends and transplant‐associated outcomes among patients ≥65 years old listed for LT with HCC.

Subscribe to